🍽️ tropisetron hcl,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Chemotherapy-Induced Nausea and Vomiting (CINV):

    • Prevention: Tropisetron is effective in preventing both acute and delayed nausea and vomiting associated with chemotherapy.
    • Improved Quality of Life: By preventing or reducing nausea and vomiting, tropisetron helps improve patients' quality of life during cancer treatment.
  2. Radiation-Induced Nausea and Vomiting (RINV):

    • Prevention: Tropisetron may also be used to prevent nausea and vomiting caused by radiation therapy.
    • Effective Control: It helps control and alleviate symptoms of nausea and vomiting in patients undergoing radiation treatment for cancer.
  3. Postoperative Nausea and Vomiting (PONV):

    • Prophylaxis: Tropisetron is sometimes used prophylactically to prevent postoperative nausea and vomiting following surgical procedures.
  4. Gastroenteritis:

    • Symptom Management: In some cases, tropisetron may be prescribed to manage nausea and vomiting associated with gastroenteritis or stomach flu.
  5. Other Conditions:

    • Motion Sickness: Tropisetron may have some efficacy in preventing motion sickness, although it is not commonly used for this purpose.
    • Other Nausea and Vomiting Disorders: Tropisetron may be prescribed off-label for other conditions causing nausea and vomiting, as determined by a healthcare professional.
;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of tropisetron hcl,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by tropisetron hcl,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Lacrimispora genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Agathobacter rectalis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of tropisetron hcl,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.5 0.5
Age-Related Macular Degeneration and Glaucoma 0.1 0.1
Allergic Rhinitis (Hay Fever) 0.1 0.1
Allergies 0.3 0.3
Allergy to milk products 0.1 0.1
Alzheimer's disease 0.4 1.3 -2.25
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.3 0.3
Ankylosing spondylitis 0.3 0.1 2
Anorexia Nervosa 0.4 -0.4
Antiphospholipid syndrome (APS) 0.3 0.3
Asthma 0.2 -0.2
Atherosclerosis 0.1 -0.1
Atrial fibrillation 0.6 0.1 5
Autism 0.5 1.2 -1.4
Barrett esophagus cancer 0.3 -0.3
Bipolar Disorder 0.1 0.1 0
Brain Trauma 0.2 -0.2
Cancer (General) 0.4 -0.4
Carcinoma 0.4 0.1 3
Celiac Disease 0.4 0.1 3
Cerebral Palsy 0.3 0.2 0.5
Chronic Fatigue Syndrome 0.9 0.9 0
Chronic Kidney Disease 0.1 0.5 -4
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.8 0.1 7
Chronic Urticaria (Hives) 0.3 0.3 0
Coagulation / Micro clot triggering bacteria 0.3 0.3 0
Colorectal Cancer 1 0.2 4
Constipation 0.1 0.1 0
Coronary artery disease 0.2 0.2
COVID-19 0.6 1.9 -2.17
Crohn's Disease 0.7 1 -0.43
cystic fibrosis 0.2 -0.2
deep vein thrombosis 0.3 -0.3
Depression 1.7 1.6 0.06
Dermatomyositis 0.3 0.3
Eczema 1.1 -1.1
Endometriosis 0.4 0.4
Epilepsy 0.7 0.1 6
Fibromyalgia 0.1 0.3 -2
Functional constipation / chronic idiopathic constipation 0.4 0.5 -0.25
gallstone disease (gsd) 0.1 -0.1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.3 0.3 0
Generalized anxiety disorder 0.1 -0.1
Glioblastoma 0.3 -0.3
Graves' disease 0.1 0.1 0
Halitosis 0.1 0.3 -2
Hashimoto's thyroiditis 0.2 0.1 1
Hidradenitis Suppurativa 0.3 0.3
High Histamine/low DAO 0.1 0.1
hyperglycemia 0.1 -0.1
hypertension (High Blood Pressure 0.4 0.9 -1.25
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 0.2 -0.2
Inflammatory Bowel Disease 1.2 1.2 0
Insomnia 0.4 0.2 1
Intelligence 0.2 0.2
Intracranial aneurysms 0.1 0.1
Irritable Bowel Syndrome 0.2 0.4 -1
Liver Cirrhosis 0.5 0.5 0
Long COVID 0.6 0.4 0.5
Low bone mineral density 0.1 -0.1
Mast Cell Issues / mastitis 0.3 0.3
ME/CFS with IBS 0.3 0.1 2
ME/CFS without IBS 0.4 0.1 3
Metabolic Syndrome 0.8 1.1 -0.38
Mood Disorders 1.7 1.6 0.06
multiple chemical sensitivity [MCS] 0.8 0.8
Multiple Sclerosis 0.8 1.2 -0.5
Multiple system atrophy (MSA) 0.1 0.1
neuropathic pain 0.3 -0.3
Neuropathy (all types) 0.3 0.3
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.3 0.6 -1
Obesity 0.6 1.1 -0.83
obsessive-compulsive disorder 0.9 0.4 1.25
Osteoarthritis 0.4 0.4
Osteoporosis 0.1 0.1 0
pancreatic cancer 0.3 0.3
Parkinson's Disease 0.3 0.9 -2
Polycystic ovary syndrome 0.1 0.1 0
primary biliary cholangitis 0.2 -0.2
Psoriasis 0.6 0.2 2
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.5 0.5 0
Rosacea 0.1 -0.1
Schizophrenia 0.3 0.1 2
Sjögren syndrome 0.3 0.6 -1
Sleep Apnea 0.2 -0.2
Slow gastric motility / Gastroparesis 0.1 0.1
Small Intestinal Bacterial Overgrowth (SIBO) 0.3 0.3
Stress / posttraumatic stress disorder 0.2 0.2 0
Systemic Lupus Erythematosus 0.7 0.1 6
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 0.4 0.3 0.33
Type 2 Diabetes 0.8 1 -0.25
Ulcerative colitis 0.6 0.4 0.5
Unhealthy Ageing 0.7 0.5 0.4

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]